Eisenmenger syndrome (ES), the most advanced form of pulmonary arterial hypertension associated with congenital heart disease, is a devastating condition that has a considerable impact on patient's life. Patients who develop ES typically exhibit one or more of a range of cardiac defects including ventricular septal defects (VSD), atrial septal defects (ASD) and patent ductus arteriosus (PDA). The nature of the congenital defect underlying ES is important because it has prognostic implications. Early diagnosis & treatment of cardiac defect before development of pulmonary hypertension is the key to definite management, otherwise only supportive management can be offered. Our patient Mr. Abdul Khaleque, 55 years old, businessman, non diabetic, non hypertensive admitted in DAMCH, cardiac unit with the complaints of shortness of breath on exertion since childhood, bluish discoloration of nails and toes for 10 years, headache and vertigo for 2 weeks. Initially it was during severe exertion and relieved by rest. Gradually the severity of breathlessness has increased. Now he has developed NYHA class III. He had history of repeated attacks of cough with expectoration of mucoid sputum with occasional scanty amount of blood which did not foul smell and did not change with posture. We diagnose him as Eisenmenger syndrome secondary to ASD and treat him with only medical measure.
Introduction:
Eisenmenger syndrome refers to any untreated congenital cardiac defect with intracardiac communication that leads pulmonary hypertension, reversal of flow and cyanosis [1] [2] [3] . The previous left to right shunt is converted into a right to left shunt secondary to elevated pulmonary artery pressure and associated pulmonary vascular disease. Lesions in ES such as large septal defect are characterized by high pulmonary pressure and/or a high pulmonary flow state. Development of the syndrome represents a point at which pulmonary hypertension is irreversible and is an indication that the cardiac lesion is likely in-operable. ES was initially described in 1897 when Victor Eisenmenger reported it on a pt with symptoms of dyspnea and cyanosis from infancy that subsequently developed heart failure and succumbed to massive haemoptysis. This was the first description of a link between a large congenital cardiac defect and the development of pulmonary hypertension 4 .
ES can cause serious complication in pregnancy, maternal mortality ranges from 30% to 40% and may be attributed to syncope, thromembolism, hypovolemia, haemoptysis or preclampsia. Most of the death occurs either during delivery or within the first week. Pregnant women with ES should be hospitalized after 20th weeks of pregnancy.
ES is more common with large VSD or PDA than with ASD
5
. Patients with ES are at particular risk for abrupt changes in afterload that exacerbate right to left shunting such as vasodilation, anaesthesia and pregnancy. During the past 50 yrs, the prevalence of ES in the western world has reduced by an estimated 50%, resulting from advances in surgery and pediatric cardiology.
ES is still seen in older patients and occasionally in younger patients. They can survive 30 yrs or more after the onset of the syndrome.
ASD in which pulmonary flow is increased 50% above systemic flow (Flow rate of 1.5:1) are often large enough to be clinically recognizable and should be closed surgically. Closure can also be accomplished at cardiac catheterization using implantable closure devices. Severe pulmonary hypertension and shunt reversal are both contraindication to surgery 6 .
Case Report: If the hole (ASD) in the heart is identified before it causes pulmonary hypertension. It can normally be repaired surgically thus can prevent the disease. After development of pulmonary hypertension heart lung transplant or lung transplant with repair of the heart is a possible option.
Severe pulmonary hypertension and shunt reversal are both contraindication to surgery. Our patient Mr. Abdul Khaleque is an elderly patient and already developed pulmonary hypertension. So, he is not a suitable candidate for surgical correction and we treat him medically.
Conclusion:
ES, the most advanced form of pulmonary arterial hypertension associated with congenital heart disease is a devastating condition that has a considerable impact on patient's life. Early diagnosis and operative treatment has a good prognostic value but late diagnosis with development of pulmonary hypertension and heart failure bear a bad prognosis. Most of the patients die subsequently due to heart failure, cardiac arrhythmia and thromboembolic cerebrovascular disease. Continued research to quantify the value of earlier intervention, combined regimens of targeted therapies and the potential to reverse pulmonary vascular remodeling in pulmonary artery hypertension in congenital heart disease is warranted.
We diagnosed him as Eisenmenger syndrome secondary to ASD and treated by medical measures with significant improvement.
Discussions:
A number of congenital heart defects can cause ES including ASD, VSD, PDA and more complex types of acyanotic heart disease. ES is more common with VSD or PDA than with ASD 2 .
ES is still seen in older patients and occasionally in younger patients. ES patient survive 30 years or more after the onset of the syndrome. Early diagnosis and surgical treatment have a good prognostic value. If a patient is diagnosed at later stage, severe pulmonary hypertension and heart failure develop and the prognosis is bad 
